Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could immunotherapy spare some colon cancer patients from surgery?

NCT ID NCT07409844

Disease control Sponsor: Ismail Gögenur Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests giving an immunotherapy drug (pembrolizumab) before surgery to people with a specific type of colon cancer (dMMR). The goal is to see if the drug can shrink or eliminate the tumor so some patients may avoid surgery and instead be closely monitored. About 152 adults with stage I to III dMMR colon cancer will join this phase 2 trial across 13 hospitals in Denmark.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 152 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Written informed consent 3. Clinical UICC stage I-III dMMR colon carcinoma 4. Indication for elective curative-intent surgery 5. ECOG status 0-2 Exclusion Criteria: 1. Patients deemed to be non-surgical candidates by MDT 2. Patients with a need for emergent surgery due to tumour obstruction 3. Contraindications to pembrolizumab, including allergy and hypersensitivity reactions, assessed by the study investigator(s) 4. Any serious or uncontrolled medical disorder, including other malignant disease, that may increase the risk associated with participation or drug administration. 5. Patients with colonic stents Additional Circumstances: In the following circumstances, eligibility will be individually verified: * Synchronous colonic tumours (may be included if other lesions are biopsy-verified with dMMR status) * Concurrent tumours (e.g., patients with prostate cancer may be included if this does not hinder their other cancer treatment or assessments of efficacy) In the following circumstance patients may be excluded from the PROMs outcomes: * Danish language skills insufficient to answer PROMs * Unable to use eBoks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer stage I are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer Lynch syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon cancer stage I Colon cancer stage II/III DMMR colorectal cancer Immunotherapy Pembrolizumab

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zealand University Hospital

    Køge, 4600, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.